Events News News & Events > 2020 Jun
We are pleased to announce that Urosphere will be presenting its unique Patient-Derived Xenograft (PDX) bank of prostate cancers at AACR Virtual Meeting II. Poster #1668. June 22 - 24, 2020 Virtual Meeting II Click to view our abstract and register to see the poster on June, 22nd! https://www.abstractsonline.com/pp8/#!/9045/presentation/4863
Read moreNews > 2020 May
Last December, the company has acquired Urolead, a company dedicated to uro-oncology and particularly to the development of Patient-Derived Xenografts (PDX) models for kidney, bladder and prostate cancers. Urolead’s expertise and PDX Biobank reinforces Urosphere’s activities providing a full package of specifically relevant models in oncology, from cells to PDXs. "The acquisition of Urolead is an essential part of our development strategy aiming at offering a full package of drug discovery portfolio of services and capabilities in urology” said Dr. Philippe Lluel, CEO of Urosphere. "This is an exciting development for Urosphere as we continue to grow and meet the needs of our clients." The company broadens its portofolio of preclinical models and expands its offer from services, co-development of molecules to licensing of PDX models. For further information, please do not hesitate to contact us contact@urosphere.com
Read moreEvents News News & Events > 2019 Mar
Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019).
Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues.
It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.
News News & Events > 2018 May
Voir le communiqué de presse
Read moreEvents News News & Events > 2017 Oct
Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.
Read more